JP2012518624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518624A5 JP2012518624A5 JP2011550652A JP2011550652A JP2012518624A5 JP 2012518624 A5 JP2012518624 A5 JP 2012518624A5 JP 2011550652 A JP2011550652 A JP 2011550652A JP 2011550652 A JP2011550652 A JP 2011550652A JP 2012518624 A5 JP2012518624 A5 JP 2012518624A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- toxin
- difficile
- composition according
- sheep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0902851A GB0902851D0 (en) | 2009-02-20 | 2009-02-20 | Antibodies to clostridium difficile toxins |
| GB0902851.5 | 2009-02-20 | ||
| GB0916153.0 | 2009-09-15 | ||
| GB0916153A GB0916153D0 (en) | 2009-09-15 | 2009-09-15 | Antibodies to clostridium difficile toxins |
| PCT/GB2010/050288 WO2010094970A1 (en) | 2009-02-20 | 2010-02-19 | Antibodies to clostridium difficile toxins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518624A JP2012518624A (ja) | 2012-08-16 |
| JP2012518624A5 true JP2012518624A5 (https=) | 2013-03-07 |
| JP5740714B2 JP5740714B2 (ja) | 2015-06-24 |
Family
ID=42109880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550652A Active JP5740714B2 (ja) | 2009-02-20 | 2010-02-19 | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8709428B2 (https=) |
| EP (1) | EP2405940B1 (https=) |
| JP (1) | JP5740714B2 (https=) |
| CN (1) | CN102365097A (https=) |
| AU (1) | AU2010215275B2 (https=) |
| CA (1) | CA2752815A1 (https=) |
| WO (1) | WO2010094970A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| US8431361B2 (en) * | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| TWI815599B (zh) * | 2011-04-22 | 2023-09-11 | 美商惠氏有限責任公司 | 與難養芽胞梭菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）之突變毒素有關之組成物及彼之方法 |
| GB201110712D0 (en) | 2011-06-23 | 2011-08-10 | Univ Ulster | Diagnostic methods |
| PL2758432T3 (pl) * | 2011-09-16 | 2019-08-30 | Ucb Biopharma Sprl | Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile |
| US10364298B2 (en) | 2011-11-18 | 2019-07-30 | National Research Council Of Canada | Clostridium difficile lipoteichoic acid and uses thereof |
| WO2013084071A2 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| DE102011121237A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| AR090219A1 (es) | 2012-03-02 | 2014-10-29 | Regeneron Pharma | Anticuerpos humanos frente a toxinas de clostridium difficile |
| WO2014061783A1 (ja) | 2012-10-19 | 2014-04-24 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| CN109776676A (zh) * | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| CA2909636C (en) * | 2013-04-19 | 2023-08-22 | Dena Lyras | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
| CN105451762A (zh) * | 2013-04-22 | 2016-03-30 | 俄克拉荷马州大学评议会 | 艰难梭菌疫苗及使用方法 |
| CN103665141B (zh) * | 2013-12-31 | 2015-09-16 | 北京大学 | 与艰难梭菌细胞毒素b相互作用的蛋白 |
| US10890583B2 (en) * | 2014-04-01 | 2021-01-12 | Institut Pasteur | Predictive value of Clostridium difficile-specific immune response for recurrence and disease outcome |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| USD952157S1 (en) | 2020-06-19 | 2022-05-17 | Qualigen Inc. | Whole blood treatment cartridge |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| EP0779819A1 (en) | 1994-09-06 | 1997-06-25 | Galagen Inc. | Therapeutic treatment of clostridium difficile associated diseases |
| US6096310A (en) | 1997-04-15 | 2000-08-01 | Bier; Milan | Oral immunotherapy of bacterial overgrowth |
| EP1000155A1 (en) | 1997-06-20 | 2000-05-17 | QUEEN MARY & WESTFIELD COLLEGE | Immunogenic fragments of toxin a of clostridium difficile |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
| US20020009429A1 (en) | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| GB0205206D0 (en) | 2002-03-06 | 2002-04-17 | Oxoid Ltd | Synthetic peptides |
| WO2004041857A2 (en) | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| DK2270045T3 (en) * | 2004-02-06 | 2015-04-07 | Univ Massachusetts | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF |
| WO2006071877A2 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| CN101363867B (zh) | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2010
- 2010-02-19 AU AU2010215275A patent/AU2010215275B2/en active Active
- 2010-02-19 CN CN2010800086731A patent/CN102365097A/zh active Pending
- 2010-02-19 JP JP2011550652A patent/JP5740714B2/ja active Active
- 2010-02-19 CA CA2752815A patent/CA2752815A1/en not_active Abandoned
- 2010-02-19 US US13/202,557 patent/US8709428B2/en active Active
- 2010-02-19 WO PCT/GB2010/050288 patent/WO2010094970A1/en not_active Ceased
- 2010-02-19 EP EP10706731.6A patent/EP2405940B1/en active Active
-
2014
- 2014-03-18 US US14/218,854 patent/US20150010580A1/en not_active Abandoned